Drug Investigation

, Volume 3, Issue 3, pp 157–161 | Cite as

Intravenous Lidoflazine in Healthy Volunteers

  • Bo Odlind
  • Ulf Björklund
  • Nils-Otto Ahnfelt
Original Research Article


Lidoflazine, an antianginal agent with some calcium antagonistic properties, has been advocated to protect tissues against ischaemic damage. Previous studies of the pharmacokinetics of lidoflazine have only concerned oral administration. Lidoflazine 0.5 and 1.0 mg/kg bodyweight was given intravenously (10-minute infusion) to 7 healthy volunteers (an eighth subject received the low dose only). Blood samples were drawn at frequent intervals, and urine was collected at intervals.

Peak plasma concentrations measured by gas chromatography ranged from 79 to 176 µg/L after 0.5 mg/kg and from 129 to 1400 µg/L after 1.0 mg/kg. The plasma concentration-time curves showed a triexponential decay, with a mean half-time of the elimination phases α, β and γ of 3.4 minutes, 2.6 hours and 16.4 hours, respectively. The largest fraction of dose, about 75%, was eliminated during the third phase. At 5 to 8 hours a second peak appeared in some of the subjects, which could reflect enterohepatic circulation of the drug. The volume of distribution (Vss) averaged 10.4 L/kg. Plasma clearance averaged 0.59 L/kg/h. Urinary recovery was less than 10% of unchanged drug.

In summary, lidoflazine is initially rapidly eliminated from the circulation, probably due to a combination of extensive tissue distribution and uptake by the liver (metabolism). After 4 to 6 hours the plasma concentration falls much more slowly possibly reflecting release from tissue binding (lidoflazine has a high lipid solubility) and, in some cases, possibly enterohepatic recirculation. The terminal elimination phase (γ) will influence the steady-state pharmacokinetics the most. Conditions affecting the organ distribution of blood flow, e.g. shock or physical exercise, could have an important influence on the pharmacokinetics of lidoflazine.


Drug Invest Liver Blood Flow Terminal Elimination Phase Antianginal Agent High Lipid Solubility 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brain Resuscitation Clinical Trial II (BRCT II) Study Group. A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest. New England Journal of Medicine 324: 1225–1231, 1991CrossRefGoogle Scholar
  2. Flameng W, Daenen W, Borgers M, Thone F, Vusse GJ, et al. Cardioprotective effects of lidoflazine in extensive aortocoronary bypass surgery. Journal of Thoracic and Cardiovascular Surgery 85: 758–769, 1983PubMedGoogle Scholar
  3. Gibaldi M, Perrier D. Pharmacokinetics: drugs and the pharmaceutical sciences, Vol. 1, Marcel Dekker Inc, New York, 1975Google Scholar
  4. Müller-Suur R, Odlind B, Nordgren L, Landelius J. Intravenous lidoflazine in healthy volunteers: haemodynamic, ECG and echocardiographic effects. Drug Investigation 3: 92–98, 1991Google Scholar
  5. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications, Lea & Febiger, New York, 1980Google Scholar
  6. Sheiner LB. ELSFIT: a program for the extended least squares fit to individual pharmacokinetic data, Users Manual, Division of Clinical Pharmacology, University of California, San Francisco, 1981Google Scholar
  7. Vanhoutte PM, Van Nueten JM. The pharmacology of lidoflazine. Royal Society of Medicine. International Congress Symposium Series 29: 61–77, 1980Google Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Bo Odlind
    • 1
  • Ulf Björklund
    • 1
  • Nils-Otto Ahnfelt
    • 1
  1. 1.Departments of Medical Pharmacology, BMCUppsala University and Research and Development, Pharmacia LEO Therapeutics ABUppsalaSweden

Personalised recommendations